Maynard Um
-
-
-
-
-
-
-
Cartesian advances Descartes-08 trials across multiple autoimmune conditions
-
-
-
-
-
-
-
Wedbush Starts Cartesian Therapeutics (RNAC) at Outperform
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) PT Lowered to $40 at H.C. Wainwright
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
-
-
-
-
-
-
-
Oppenheimer Downgrades Cartesian Therapeutics (RNAC) to Perform
-
-
-
396,421 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

